March 20, 2020
At Radius Health, safety and well-being remain our highest priority. In response to the spread of COVID-19, we are addressing the issue with the seriousness it deserves and taking measures to help ensure the health of our employees, the healthcare providers (HCPs) and patients we serve, and their families and communities.
With safety a top priority, we have instituted a mandatory work-from-home schedule for our employees for the time being, including our commercial and clinical teams, and we have enhanced the utilization of technical tools and capabilities to accomplish secure remote access and conduct of virtual business.
We have taken several measures to ensure patients and HCPs continue to have access to our medicine and available resources. Outlined below are some of these virtual measures and related important information.
As a reminder, TYMLOS®® (abaloparatide) injection is a self-injectable and does not require patients to return to the office for treatment. Additionally, TYMLOS is generally dispensed by specialty pharmacies who ship prescriptions via mail, so patients served by them may be able to avoid traveling to their local pharmacy to refill prescriptions.
We are also offering virtual representative interactions to connect with health care professionals and assist their offices with continued access to TYMLOS tools and resources. Additionally, we have converted our clinical educator team to deliver virtual injection support to our patients. Operationally, we have implemented online processes to supply samples and promotional material to HCP offices.
For additional information regarding Radius products, visit: https://radiuspharm.com/contact/
Please see the full prescribing information here
As the global COVID-19 pandemic evolves, we are giving careful attention to the supply of TYMLOS and our investigational products. It’s important to note that our supply chain for TYMLOS is mostly located in Europe and we currently believe we have sufficient inventory on hand. In addition, we also currently believe we have sufficient inventories of our investigational products, abaloparatide-patch and elacestrant (RAD1901), to support our ongoing clinical trials. We are working closely with our contract manufacturing organizations to mitigate risks to our continuity of supply.
On the clinical front, as explained during our recent corporate updates, recruitment in our three Phase 3 trials has been progressing well. However, the strict measures taken globally to prevent the spreading of the virus has the potential to impact enrollment timelines for our clinical studies, as patients may choose not to attend physician offices and offices reduce in-person visits to protect patients and staff. In the meantime, we are working closely with our clinical sites and clinical research organizations to monitor the situation and evaluate potential contingency measures to ensure the safety of trial participants such as alternative means of getting the trial drug to clinical study patients via home drug delivery.
Based on information presently available to us, we are not changing our previously issued financial guidance at this time. We will, however, be monitoring the impact of a rapidly changing market environment and expect to make an update regarding the impact of the COVID-19 pandemic on our business no later than in our Q1 earnings call in May 2020.
For additional information related to Radius Health, TYMLOS and our other programs, please refer to our filings with the Securities and Exchange Commission.